Egfr

Edit

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

PR Newswire 18 Dec 2025

... targeted therapy for patients with EGFR+ mNSCLC ... Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC – Final Overall Survival from MARIPOSA [ELCC abstract #40].

Edit

Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma (Glenmark Pharmaceuticals Limited)

Public Technologies 16 Dec 2025

) Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma ... our ability to serve patients with EGFR-mutated lung cancer.

Edit

‘I am 74; recent blood report shows my kidney function (eGFR) as 53. How can I bring it to a normal level > 59?’

Indian Express 11 Dec 2025

Get kidney tests every 6-12 months .

Edit

RYBREVANT®▼(amivantamab) in combination with carboplatin and pemetrexed is accepted for use within NHS Scotland as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations

Pharmiweb 09 Dec 2025

“EGFR+ UK is delighted that the Scottish Medicines Consortium has approved amivantamab with chemotherapy for eligible patients in Scotland diagnosed with EGFR Exon 20 insertion mutations NSCLC,” said Prof.

Edit

ORIC� Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 ...

Nasdaq Globe Newswire 03 Dec 2025

Company to host a conference call and webcast on Saturday, December 6, 2025, at 8.00 pm ET. Company to host a conference call and webcast on Saturday, December 6, 2025, at 8.00 pm ET ... .

Edit

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR

Enid News & Eagle 03 Dec 2025

SOUTH SAN FRANCISCO and SAN DIEGO, Dec ... (Nasdaq.

Edit

‘I am 52, not diabetic, BP 130\/90 but my creatinine is 1.35 and eGFR 55. What do I do to stop further deterioration? My weight is 90 kg’

Indian Express 25 Nov 2025

Check important metabolic markers ... .

Edit

BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking ...

The Eagle-Tribune 21 Nov 2025

BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, ...

Edit

Final Overall Survival Analysis : HARMONi-A Study Ivonescimab + chemotherapy versus Chemotherapy In patients with EGFR-mutant NSCLC progressed on EGFR TKI (Summit Therapeutics Inc)

Public Technologies 21 Nov 2025

EGFR-mutant NSCLC progressed on EGFR TKI ... In an earlier PFS interin analysis of HARMONi-A1, ivonescinab plus chenotherapy significantly prolonged PFS conpared with chenotherapy alone in patients with EGFR+ NSCLC progressed with EGFR-TKI treatnent..

Edit

BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC

PR Newswire 21 Nov 2025

BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their partnership spanning over two years ... EGFR-targeting antibody-drug conjugate (ADC).

Edit

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

PR Newswire 20 Nov 2025

CLN-081/TAS6417) monotherapy in patients with NSCLC harboring EGFR ex20ins mutations who have received prior therapy ... CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR.

Edit

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (Cullinan Therapeutics Inc)

Public Technologies 20 Nov 2025

CLN-081/TAS6417) monotherapy in patients with NSCLC harboring EGFR ex20ins mutations who have received prior therapy ... CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR.

Edit

Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, ...

Business Wire 10 Nov 2025

SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate ... .

Edit

SITC 2025 Poster Presentation: Dual targeting of TGF-b and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer cell lines (Bicara Therapeutics Inc)

Public Technologies 08 Nov 2025

) Dual targeting of TGF-β and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer cell lines ... Dual targeting of EGFR and TGF-β with ficerafusp alfa showed improved ... EGFR per cell.

Edit

BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC

Citizen Tribune 05 Nov 2025

BioDlink helps Lepu Biopharma win China's marketing approval for ...

Podcasts:

Latest News for: egfr

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma (Glenmark Pharmaceuticals Limited)

‘I am 74; recent blood report shows my kidney function (eGFR) as 53. How can I bring it to a normal level > 59?’

RYBREVANT®▼(amivantamab) in combination with carboplatin and pemetrexed is accepted for use within NHS Scotland as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations

ORIC� Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 ...

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR

‘I am 52, not diabetic, BP 130\/90 but my creatinine is 1.35 and eGFR 55. What do I do to stop further deterioration? My weight is 90 kg’

BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking ...

Final Overall Survival Analysis : HARMONi-A Study Ivonescimab + chemotherapy versus Chemotherapy In patients with EGFR-mutant NSCLC progressed on EGFR TKI (Summit Therapeutics Inc)

BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, ...

SITC 2025 Poster Presentation: Dual targeting of TGF-b and EGFR with ficerafusp alfa shows superior antitumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer cell lines (Bicara Therapeutics Inc)

BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC

Article Search

EXPLORE WN.com